Polysaccharides and glycolipids of Mycobacterium tuberculosis and their induced immune responses
- PMID: 39008002
- DOI: 10.1111/sji.13261
Polysaccharides and glycolipids of Mycobacterium tuberculosis and their induced immune responses
Abstract
Tuberculosis (TB) is a chronic infectious disease mainly caused by Mycobacterium tuberculosis (M. tuberculosis). The structures of polysaccharides and glycolipids at M. tuberculosis cell wall vary among different strains, which affect the physiology and pathogenesis of mycobacteria by activating or inhibiting innate and acquired immunity. Among them, some components such as lipomannan (LM) and lipoarabinomannan (LAM) activate innate immunity by recognizing some kinds of pattern recognition receptors (PRRs) like Toll-like receptors, while other components like mannose-capped lipoarabinomannan (ManLAM) could prevent innate immune responses by inhibiting the secretion of pro-inflammatory cytokines and maturation of phagosomes. In addition, many glycolipids can activate natural killer T (NKT) cells and CD1-restricted T cells to produce interferon-γ (IFN-γ). Furthermore, humoral immunity against cell wall components, such as antibodies against LAM, plays a role in immunity against M. tuberculosis infection. Cell wall polysaccharides and glycolipids of M. tuberculosis have potential applications as antigens and adjuvants for novel TB subunit vaccines.
Keywords: Mycobacterium tuberculosis; adaptive immunity; glycolipids; innate immunity; polysaccharides; subunit vaccine.
© 2023 The Scandinavian Foundation for Immunology.
Similar articles
-
Lipoarabinomannan, and its related glycolipids, induce divergent and opposing immune responses to Mycobacterium tuberculosis depending on structural diversity and experimental variations.Tuberculosis (Edinb). 2016 Jan;96:120-30. doi: 10.1016/j.tube.2015.09.005. Epub 2015 Oct 28. Tuberculosis (Edinb). 2016. PMID: 26586646 Review.
-
Lipoarabinomannan in Active and Passive Protection Against Tuberculosis.Front Immunol. 2019 Sep 11;10:1968. doi: 10.3389/fimmu.2019.01968. eCollection 2019. Front Immunol. 2019. PMID: 31572351 Free PMC article. Review.
-
CD1d and natural killer T cells in immunity to Mycobacterium tuberculosis.Adv Exp Med Biol. 2013;783:199-223. doi: 10.1007/978-1-4614-6111-1_11. Adv Exp Med Biol. 2013. PMID: 23468111 Review.
-
Evaluation of the humoral immune response and cross reactivity against Mycobacterium tuberculosis of mice immunized with liposomes containing glycolipids of Mycobacterium smegmatis.BMC Immunol. 2013;14 Suppl 1(Suppl 1):S13. doi: 10.1186/1471-2172-14-S1-S13. Epub 2013 Feb 25. BMC Immunol. 2013. PMID: 23458474 Free PMC article.
-
Critical roles for lipomannan and lipoarabinomannan in cell wall integrity of mycobacteria and pathogenesis of tuberculosis.mBio. 2013 Feb 19;4(1):e00472-12. doi: 10.1128/mBio.00472-12. mBio. 2013. PMID: 23422411 Free PMC article.
Cited by
-
Cytotoxic granules and effector molecules from immune cells in tuberculosis: Mechanisms of host defense and therapeutic potential.Virulence. 2025 Dec;16(1):2542466. doi: 10.1080/21505594.2025.2542466. Epub 2025 Aug 18. Virulence. 2025. PMID: 40825006 Free PMC article. Review.
-
Advances in Host-Pathogen Interactions in Tuberculosis: Emerging Strategies for Therapeutic Intervention.Int J Mol Sci. 2025 Feb 14;26(4):1621. doi: 10.3390/ijms26041621. Int J Mol Sci. 2025. PMID: 40004082 Free PMC article. Review.
-
Emerging Extracellular Molecular Targets for Innovative Pharmacological Approaches to Resistant Mtb Infection.Biomolecules. 2023 Jun 16;13(6):999. doi: 10.3390/biom13060999. Biomolecules. 2023. PMID: 37371579 Free PMC article. Review.
References
REFERENCES
-
- Furin J, Cox H, Pai M. Tuberculosis. Lancet (London, England). 2019;393(10181):1642‐1656.
-
- Sia JK, Rengarajan J. Immunology of mycobacterium tuberculosis infections. Microbiol Spectr. 2019;7(4).
-
- Fatima S, Kumari A, Das G, Dwivedi VP. Tuberculosis vaccine: a journey from BCG to present. Life Sci. 2020;252:117594.
-
- Dockrell HM, Smith SG. What have we learnt about BCG vaccination in the last 20 years? Front Immunol. 2017;8:1134.
-
- Achkar JM, Prados‐Rosales R. Updates on antibody functions in mycobacterium tuberculosis infection and their relevance for developing a vaccine against tuberculosis. Curr Opin Immunol. 2018;53:30‐37.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical